Asset Details
Do you wish to reserve the book?
Exploiting gene dependency to inform drug development for multiple myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Exploiting gene dependency to inform drug development for multiple myeloma
Do you wish to request the book?
Exploiting gene dependency to inform drug development for multiple myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Exploiting gene dependency to inform drug development for multiple myeloma
2022
Overview
Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for developing new therapeutic agents to treat MM and overcome drug resistance. To explore this possibility, we analysed DepMap project data identifying 23 MM essential genes and examined the relationship between their expression and patient outcome in three independent series totalling 1503 cases. The expression of
TCF3
and
FLVCR1
were both significantly associated with progression-free survival.
IKBKB
is already a drug target in other diseases, offering the prospect of repurposing to treat MM, while
PIM2
is currently being investigated as a treatment for the disease. Our analysis supports the rationale of using large-scale genetic perturbation screens to guide the development of new therapeutic agents for MM.
